Cingulate Therapeutics

11 articles with Cingulate Therapeutics

• Cingulate Therapeutics to Present at Biotech Showcase™ 2019 in San Francisco

  1/7/2019

  Cingulate Therapeutics LLC announced that Shane J. Schaffer, PharmD, Chairman and CEO of Cingulate Therapeutics, will present at Biotech Showcase 2019 to be held January 6-9, 2019, at the Hilton San Francisco Union Square

• Cingulate Therapeutics Announces $7.5M Equity Investment from Werth Family Investment Associates

  7/11/2018

  Industry veteran Peter J. Werth to join Cingulate Therapeutics Board of Directors

• Cingulate Therapeutics Strengthens Leadership with Two New Board Appointments

  5/31/2018

  Cingulate Therapeutics LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing its precision timed release drug delivery platform technology, today announced the appointment of Jeff Conroy and Jeff Hargroves to its Board of Directors

• Cingulate Therapeutics Appoints Laurie Myers, PhD, MBA as Chief Operating Officer

  4/2/2018

  Dr. Myers currently serves as a founding member of the Cingulate Therapeutics Board of Directors.

• Cingulate Therapeutics Presents New Data from its First in Human Proof of Concept Trial of CTX-1301 at the 2018 APSARD Annual Meeting

  1/15/2018

  Overall, researchers found that CTX-1301 delivered consistent tri-modal release of the dexmethylphenidate hydrochloride.

• Cingulate Therapeutics Appoints Experienced Lead Investigator Matthew Brams, MD as CMO

  1/9/2018

  Dr. Brams is a Co-Founder of Cingulate Therapeutics and currently serves as a member of the Board of Directors.

• Cingulate Therapeutics to Present in Vivo Pharmacokinetic Data Demonstrating Consistent Tri-Phasic Release Profile of Lead Compound at the AAPS Annual Meeting

  11/15/2017

  The study evaluated CTX-1301, Cingulate's proprietary, first-line stimulant medication for the treatment of ADHD, utilizing an innovative, proprietary timed release technology OralogiK developed by CTx's partner BDD.

• Cingulate Partners With Camargo Pharmaceutical Services For Development Programs

  8/8/2017

• Cingulate Appoints Strategic Finance Veteran Louis G. Van Horn As Chief Financial Officer

  7/10/2017

• Cingulate Moves HQ To Aratana's Old Space To Accommodate Growth

  6/15/2017

• Cingulate Initiates First Human Clinical Trial

  5/31/2017